UnitedHealth's Strategy to Replace Humira with Affordable Biosimilars
UnitedHealth's Strategic Move
In a daring approach to healthcare costs, UnitedHealth has announced a plan to phase out the well-known arthritis medication Humira from its preferred-drug lists starting in 2025. This decision comes as the company emphasizes the availability of cheaper biosimilar alternatives, enabling better affordability for patients.
Impact on Patients and Insurers
- The removal of Humira may affect many patients who rely on it for arthritis treatment.
- Insurers can benefit from reduced costs associated with prescribing biosimilars.
- This move could lead to greater acceptance of biosimilars in the healthcare industry.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.